Turning Point Therapeutics logo
Turning Point Therapeutics TPTX

Quarterly report 2022-Q2
added 08-08-2022

report update icon

Turning Point Therapeutics Operating Income 2011-2026 | TPTX

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula
Operating profit = Revenue – Operating expenses
Features of the metric
  • Evaluates business efficiency
    Shows how well the company controls its production and administrative costs.
  • Independent of financial structure
    Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
  • Main source for growth
    High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Turning Point Therapeutics

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-238 M -162 M -77.7 M -25.6 M -16.7 M - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-16.7 M -238 M -104 M

Quarterly Operating Income Turning Point Therapeutics

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - -124 M -74.9 M - -66.7 M -56.7 M -36 M -47.9 M -18.5 M -32.7 M -62.6 M -23.1 M -22.1 M -18.5 M -14.1 M -9.48 M -6.13 M -5.17 M -4.86 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
-4.86 M -124 M -36.7 M

Operating Income of other stocks in the Biotechnology industry

Issuer Operating Income Price % 24h Market Cap Country
Burford Capital Limited Burford Capital Limited
BUR
242 M $ 4.74 0.53 % $ 761 M britainBritain
Cabaletta Bio Cabaletta Bio
CABA
-172 M $ 3.33 2.15 % $ 335 M usaUSA
MorphoSys AG MorphoSys AG
MOR
-508 M - 2.43 % $ 254 M germanyGermany
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-9.95 M $ 3.07 0.49 % $ 5.05 M israelIsrael
Acorda Therapeutics Acorda Therapeutics
ACOR
-265 M - -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-139 M - - $ 86.2 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
502 M $ 332.58 -2.01 % $ 43.6 B usaUSA
AlloVir AlloVir
ALVR
-46.2 M - 4.14 % $ 49.1 M usaUSA
Genfit SA Genfit SA
GNFT
31.8 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-26.8 M - -13.47 % $ 169 M franceFrance
Aligos Therapeutics Aligos Therapeutics
ALGS
-88 M $ 7.51 -14.07 % $ 74.2 M usaUSA
Allakos Allakos
ALLK
-196 M - - $ 28.6 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
60.3 M $ 2.11 2.77 % $ 439 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
-31 M $ 0.82 - $ 27.9 M israelIsrael
Applied Molecular Transport Applied Molecular Transport
AMTI
-127 M - - $ 10.1 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
-70.7 M $ 32.35 -0.2 % $ 419 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-7 M - -18.52 % $ 27.3 M britainBritain
Applied Therapeutics Applied Therapeutics
APLT
-64.5 M - - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
-62.6 M - -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
-70.8 M - -13.39 % $ 1.45 M usaUSA
Galapagos NV Galapagos NV
GLPG
-166 M $ 28.99 0.36 % $ 2.69 B belgiumBelgium
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
140 M $ 21.36 -0.09 % $ 998 M usaUSA
Genmab A/S Genmab A/S
GMAB
2.64 B $ 29.02 -0.14 % $ 18.6 B danmarkDanmark
GT Biopharma GT Biopharma
GTBP
-12.4 M $ 0.38 -3.34 % $ 2.1 M usaUSA
BioNTech SE BioNTech SE
BNTX
15.3 B $ 99.43 1.03 % $ 27.2 B germanyGermany
Advaxis Advaxis
ADXS
-36.3 M - -9.65 % $ 45.9 M usaUSA
Hoth Therapeutics Hoth Therapeutics
HOTH
-12.4 M $ 0.68 4.58 % $ 9.39 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-8.67 M - 5.93 % $ 314 M canadaCanada
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
208 M $ 29.37 0.27 % $ 1.69 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
-24 M - -10.17 % $ 12.2 K usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
1.65 M $ 7.61 -1.55 % $ 68.7 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-210 M - - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
23.5 M $ 1.54 -1.28 % $ 396 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-17.7 M - - $ 26.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
-71.1 M $ 4.18 0.6 % $ 447 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
-12.2 M $ 24.39 -2.79 % $ 3.1 B usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-9.95 M - -2.5 % $ 5.88 M usaUSA
Immatics N.V. Immatics N.V.
IMTX
-86.3 M $ 10.9 -0.46 % $ 686 M germanyGermany
AIkido Pharma AIkido Pharma
AIKI
-55.7 M - 1.93 % $ 17.4 M usaUSA
Incyte Corporation Incyte Corporation
INCY
1.51 B $ 97.43 -0.27 % $ 19 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
37.1 M - -4.8 % $ 255 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-271 M $ 1.46 -1.49 % $ 389 M britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
447 M - 0.49 % $ 251 B cayman-islandsCayman-islands
Innate Pharma S.A. Innate Pharma S.A.
IPHA
-47.8 M $ 1.71 4.91 % $ 235 M franceFrance